According to the NCI website, lurbinectedin is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. . Check for active clinical trials using this agent. (NCI Thesaurus)
According to WIKI in “Small-cell carcinoma”
Lurbinectedin demonstrated an overall response rate (ORR) of 35.2% in relapsed small cell lung cancer trial. Overall survival rate for patients with sensitive disease (chemotherapy-free interval of 90 days or longer) was 15.2 months, and 5.1 months for patients with resistant disease (chemotherapy-free interval of less than 90 days).  Lurbinectedin is currently available in the U.S. under Expanded Access Program (EAP).
Summary of the following 2 studies:
Trigo J, et al "Lurbinectedin as a second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial" Lancet Oncol 2020; 21: 645-54.
Arrieta O, et al "New opportunities in a challenging disease: Lurbinectedin for relapsed small-cell lung cancer" Lancet Oncol 2020; 21: 605-607.
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute